An internal standard for the quantification of (–)-ropivacaine
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

(–)-Ropivacaine-d7 (hydrochloride)

Item No. 26495

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(S)-N-(2,6-dimethylphenyl)-1-(propyl-d7)piperidine-2-carboxamide, monohydrochloride
CAS Number
1217667-10-1
Synonyms
  • (S)-Ropivacaine-d7
Molecular Formula
C17H19D7N2O • HCl
Formula Weight
317.9
Purity
≥99% deuterated forms (d1-d7)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
Methanol: solubleWater: soluble
SMILES
CC1=CC=CC(C)=C1NC([C@H]2N(C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])CCCC2)=O.Cl
InChi Code
InChI=1S/C17H26N2O.ClH/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3;/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20);1H/t15-;/m0./s1/i1D3,4D2,11D2;
InChi Key
NDNSIBYYUOEUSV-JRDUKJLFSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $121

    Add

    1 mg

    $218

    Add
    Product Description

    (–)-Ropivacaine-d7 is intended for use as an internal standard for the quantification of (–)-ropivacaine (Item No. 21422) by GC- or LC-MS. (–)-Ropivacaine is a potent and reversible blocker of sodium channels in nerve fibers.1 In vivo, (–)-ropivacaine induces complete impairment of proprioception, motor function, and nociception in the hindleg of rats when 100 μL of an 8 mM solution is injected percutaneously into the sciatic nerve.2 (–)-Ropivacaine depresses myocardial contractile force in isolated rat hearts less potently than (±)-ropivacaine, as well as (–)- and (±)-bupivacaine (Item No. 16618).3 Formulations containing (–)-ropivacaine have been used as local anesthetics during surgery and childbirth.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hansen, T.G. Ropivacaine: A pharmacological review. Exp. Rev. Neurother. 4(5), 781-791 (2004).

    2. Sinnott, C.J., and Strichartz, G.R. Levobupivacaine versus ropivacaine for sciatic nerve block in the rat. Reg. Anesth. Pain Med. 28(4), 294-303 (2003).

    3. Pinotti, M.F., Hepner, A., Campos, D.H., et al. Myocardial contractility impairment with racemic bupivacaine, non-racemic bupivacaine and ropivacaine. A comparative study. Acta Cir. Bras. 30(7), 484-490 (2015).